| Literature DB >> 31741623 |
Neha Singh1, Narendra Agrawal2, Ridhi Sood1, Gayatri Vishwakarma3, Dushyant Kumar4, Surender Dhanda4, Narender Tejwani1, Rayaz Ahmed2, Dinesh Bhurani2, Anurag Mehta1.
Abstract
The presence of minimal residual disease (MRD) is one of the strong predictors of disease outcome in various hematological malignancies including B-ALL and T-ALL, independent of pre-therapeutic risk factors. There is scant Indian data on MRD by flowcytometry in T-ALL including gating strategies, clinical correlation etc. The primary aim of this retrospective observational study was to define the clinico-hematologic characteristics and prognostic significance of patients with ETP/near-ETP versus non-ETP immunophenotype, especially in terms of minimal residual disease at different time points as well as event-free survival (1 year). Baseline hematologic characteristics along with post-induction (Day-35) and post-consolidation (Day-78) MRD in bone marrow samples from newly diagnosed T-ALL patients were studied. 14.3% patients had ETP-ALL immunophenotype, 11.4% were near-ETP ALL patients and the remaining 74.5% were of non-ETP subtype. The ETP/near ETP patients was significantly associated with higher risk of MRD positivity ( > 0.01%) at the end of induction in comparison to the non-ETP patients (p = 0.033). Also, these patients showed a trend towards proclivity to anemia (p = 0.06) and higher rates of induction failure (p = 0.07) However, no difference was observed between the two subgroups in terms of age, high TLC, thrombocytopenia, adverse cytogenetics, steroid responsiveness on Day + 8 of induction, MRD-positivity > 0.01% at the end of consolidation and EFS-1 year. Through this preliminary study, it can be stated clearly that ETP status is associated with MRD > 0.01% post-induction but has no significant impact on long-term survival of these patients. © Indian Society of Hematology and Blood Transfusion 2019.Entities:
Keywords: Acute lymphoblastic leukemia; Immunophenotyping; Minimal residual disease
Year: 2019 PMID: 31741623 PMCID: PMC6825102 DOI: 10.1007/s12288-019-01106-9
Source DB: PubMed Journal: Indian J Hematol Blood Transfus ISSN: 0971-4502 Impact factor: 0.900